AI Article Synopsis
- - Central nervous system involvement in multiple myeloma is rare and typically leads to a very poor prognosis, often unresponsive to treatment.
- - In a study of 13 cases in Budapest, most patients had high-risk features and some showed clonal evolution through genetic testing.
- - Treatment outcomes were generally poor, but one patient lived with a positive response to daratumumab; recent reports suggest that pomalidomide and marizomib may offer promising effects.
Article Abstract
Central nervous system involvement is a rare complication of multiple myeloma with extremely poor prognosis as it usually fails to respond to therapy. We present 13 cases diagnosed at two centers in Budapest and review the current literature. The majority of our cases presented with high-risk features initially; two had plasma cell leukemia. Repeated genetic tests showed clonal evolution in 3 cases. Treatments varied according to the era, and efficacy was poor as generally reported in the literature. Only one patient is currently alive, with 3-month follow-up, and the patient responded to daratumumab-based treatment. Recent case reports show promising effectivity of pomalidomide and marizomib.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5937370 | PMC |
| http://dx.doi.org/10.1155/2018/3970169 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!